Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japanese phase 3 single-dose CSL222 gene therapy study in adult men with severe or moderately severe hemophilia B
jRCT2033230266Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Sep 2023
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Limited. Primary endpoint: Annualized bleeding rate. Started Sep 2023; status: active, not recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on jRCT2033230266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230266.